Healthcare Weekly Report: China Resources Acquires TSL for RMB 6.212 Billion; Chinese-Originated Small Molecule Project Acquired

6.212 Billion! CRRC Makes Another Move

On August 4, 2024, Tasly (600535) announced in the evening that the company's controlling shareholder, Tasly Group, and its concert parties plan to transfer shares to China Resources Sanjiu for a consideration of 6.212 billion yuan. After the transaction is completed, the company's controlling shareholder will be changed to China Resources Sanjiu, and the actual controller will be changed to China Resources. On the same day, the company announced that upon application to the Shanghai Stock Exchange, the company's stock will resume trading at the opening on August 5, 2024. (Source: Arterial Network)

Small Molecule Project Incubated by Chinese Pharmaceutical Company Acquired

On July 29, US Pacific Time, Boehringer Ingelheim announced a deal worth up to $1.3 billion to acquire Nerio Therapeutics ("Nerio"), which was co-invested and incubated by Viva Biotech. Nerio's core pipeline is a small molecule PTPN1/2 inhibitor, an oncology pipeline in the preclinical stage. The inhibitor activates the immune system to fight cancer cells by inhibiting protein tyrosine phosphatases N1 and N2 ("PTPN1" and "PTPN2"). This acquisition will significantly strengthen Boehringer Ingelheim's immuno-oncology pipeline, with the goal of improving treatment outcomes for cancer patients. (Source: Arterial Network)

Huadong Medicine and Beijing Yimiaoshenzhou Medical Technology Co., Ltd. Reach Cooperation on CAR-T Product

On August 4, Huadong Medicine and Beijing Yimiaoshenzhou Medical Techology Co., Ltd. jointly announced that they have reached a commercialization collaboration in mainland China regarding the latter's autologous CAR-T candidate product IM19 Chimeric Antigen Receptor T-cell Injection (hereinafter referred to as "IM19 Injection"), which targets CD19. According to the agreement terms, Beijing Yimiaoshenzhou Medical Techology Co., Ltd. will receive an upfront payment of 125 million RMB and is entitled to receive registration and sales milestone payments of up to 950 million RMB. Beijing Yimiaoshenzhou Medical Techology Co., Ltd. will continue to be responsible for the development, registration, and production of IM19 Injection in mainland China. (Source: MedMerits)

China OTSUKA Pharmaceutical Co., Ltd. to Acquire Jnana

On August 1, Otsuka and Jnana Therapeutics ("Jnana" for short) jointly announced that they had reached a final agreement. According to the agreement, Otsuka will acquire Jnana, making it a wholly-owned subsidiary of Otsuka's subsidiary, Otsuka America, Inc. (OAI). Under the terms of the agreement, Otsuka will pay Jnana’s shareholders $800 million upon completion of the acquisition, along with up to $325 million in development and regulatory milestones. The total value of this transaction will reach $1.125 billion (approximately 8.15 billion yuan). Subject to customary closing conditions, the acquisition is expected to be completed in the third quarter of fiscal year 2024. (Source: Arterial Network)

Bona Biotech Secures Nearly 100 Million Yuan in Financing

On August 5, 2024, Shandong Bona Biotechnology Group Co., Ltd. announced the completion of a nearly 100-million-yuan Series A financing round. This round was led by Luxin Venture Capital, with Jigao Caijin participating as a follower, and Life Capital acting as the exclusive financial advisor. Investors in this round have strong confidence in the development prospects of Bona Biotech. They will support the company’s market expansion in the membrane separation and purification field through resource empowerment and integration, further strengthening Bona Biotech's leading position in this sector. (Source: Arterial Network)

Addgene Completes Angel Round Financing of Over RMB 10 Million

Recently, Guangzhou ID Gene Technology Co., Ltd. (hereinafter referred to as "ID Gene"), announced the completion of an angel round of financing exceeding ten million yuan, jointly invested by Yanghe Investment, Zhongda Venture Capital, and Qianhai Great Wall Fund. The funds raised from this round will be used to accelerate the company's team building, enhance R&D capabilities, expand product portfolios, and develop overseas markets. (Source: Arterial Network)

Fuxiang Aesthetics Completes Nearly 100 Million Yuan in Series A Financing

Recently, Fuxiang Aesthetics (Fuxiang Sital Medical Technology (Suzhou) Co., Ltd.), a leading global enterprise in silk fibroin biomaterials, has completed nearly RMB 100 million in Series A financing. This round of financing was jointly led by Yuhai Capital and Shaanxi New Era Capital, with Herui Venture Capital participating as a follow-up investor. Established in 2020, Fuxiang Aesthetics is committed to utilizing silk fibroin for biomedical tissue engineering repair and aesthetic product development. The company focuses on silk fibroin, a biomaterial known for its excellent physicochemical properties, biocompatibility, biodegradability, and lack of immunogenicity, leveraging years of industry expertise. (Source: Arterial Network)

Guyuan Medical Completes Tens of Millions of Yuan in Series A Financing

Shenzhen Guyuan Plastic Products Co., Ltd. (referred to as "Guyuan Medical"), a medical polymer materials technology enterprise, has recently completed a multi-million yuan Series A round of financing. This comes just six months after receiving capital recognition and support. The round was invested by Guiyang Venture Capital, with Zhi Jin Capital continuing to act as Guyuan Medical's long-term exclusive financial advisor. The funds from this round will be used for the construction of production lines for new medical materials and medical consumables products. (Source: Arterial Network)

26 Financings in 2024, Leading Companies in China to Go Public, Digital Therapeutics Poised for Full-Scale Outbreak

In July this year, Brain Dynamics Polaris received filing from the China Securities Regulatory Commission for its overseas issuance and listing, bringing it one step closer to becoming "China's first digital therapeutics stock." Earlier, in early June this year, Sword Health, a digital therapeutics company specializing in musculoskeletal rehabilitation, announced that it had completed a financing round of approximately $130 million. This brought Sword Health’s total financing to $340 million, with the company’s valuation reaching $3 billion, firmly establishing it as a new unicorn in the digital therapeutics field. From an industry-wide perspective, although the global healthcare investment and financing showed a phased downward trend in the first half of 2024 (H1), the "2024 H1 Global Healthcare Investment and Financing Analysis Report" pointed out that in the first half of 2024, there were 1,197 private equity investments completed in the healthcare sector globally, accumulating a total financing of $30.7 billion. Compared to the same period in 2023, due to a decrease in the number of transactions, the average financing amount increased significantly by 29.97% against the trend. Among these, the global digital health sector raised funds 317 times, totaling $4.6 billion. The data shows a year-on-year recovery. Even within China, the digital health sector was the most active area for capital investment, with 272 financing events occurring in the domestic digital health field in the first half of 2024. (Source: Vbdata.cn)

"Guiding Opinions on Improving the Long-term Mechanism for Basic Medical Insurance Enrollment"

To actively address population aging, diversification of employment forms, adapt to changes in population mobility and insurance participation needs, continuously consolidate and expand the achievements of universal insurance coverage, and strengthen the foundation of the basic medical insurance system, the following opinions are proposed to improve the long-term mechanism for basic medical insurance participation. These include: improving participation policies, refining financing policies, enhancing benefit policies, accurately monitoring participation status, coordinating participation mobilization efforts, significantly upgrading service capabilities, effectively improving healthcare experiences, clarifying department responsibilities, strengthening inter-departmental cooperation, promoting information sharing, reinforcing organizational leadership, and enhancing comprehensive evaluation, among others. (Source: Every Day Economic News)